CHICAGO — Novo Nordisk’s next-generation weight problems injection concentrating on the amylin hormone confirmed substantial weight reduction in an early research, however related efficacy throughout completely different doses and excessive charges of negative effects increase questions on which dose Novo will pursue going ahead.
Within the Section 1/2 research testing the drug, referred to as amycretin, sufferers on the best dose of 60 mg misplaced on common 24.3% of their weight at 36 weeks, whereas these on placebo misplaced 1.1%, in keeping with outcomes printed Friday within the Lancet that can even be offered on the American Diabetes Affiliation convention. These outcomes recommend amycretin might be simpler than different medicine available on the market.
In one other a part of the research testing 20-mg, 5-mg, and 1.25-mg doses of amycretin, sufferers additionally skilled substantial weight reduction, however with overlapping weight-loss curves. The discovering is uncommon since researchers sometimes count on a dose-dependent impact, the place sufferers on greater doses lose extra weight quicker.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
